Mongersen (Celgene)

Crohn's Disease Forum

Help Support Crohn's Disease Forum:

Joined
Jul 6, 2014
Messages
12
I know I've been posting a lot about my issues lately, but here's another for the books!

At my last appt with my GI, he declared that I can no longer NOT be on a medication. He put me on a high dose of prednisone (an old demon) and told me to call him with a choice after a week.
So, after doing a lot of research on Entyvio, stelara, and the like, I found that Mongersen, a new trial drug by the company Celgene is doing fairly well and I think I'm going to try it.

If I do, I will keep you all posted. Otherwise, has anyone else tried the study? Or heard anything?

:sign0085:
 
Hi loki, I am afraid that I have not heard of it, so can't help really. I do want to wish you the best and send you my support. Keep us posted on how you get on please. 💖
 
There is an article here in the forum from 12-14-15 in General IBD discussion titled Mongersen. Best to you.
 
Please let us know how it goes! I am on some other trial drugs right now and doing well but have been interested in mongersen since I read about it a year or 2 back
 
Sorry to say that I was turned away because it was more focused toward ulcerative colitis. I've been signed on to try Stelara. Everything crossed that it works. Thanks for everyone's support!
 
Mongersen is being investigated in three clinical trials sponsored by Celgene. One each for Crohn's and Ulcerative Colitis, and the third trial is also for Crohn's but hasn't started recruiting patients yet.

I suspect you were turned away from the UC trial. If that was the case try again with the Crohn's trial: https://clinicaltrials.gov/ct2/show/NCT02596893
 
Bad news for Mongersen... the phase II study showed lack of efficacy for CD.

https://www.forbes.com/sites/matthe...ne-bought-for-710-million-fails/#f5c4e8d23777

"Today, Celgene announced that after consulting the data safety and monitoring committee that was overseeing the main mongersen study, called REVOLVE, it had decided to stop developing the drug. It cited a futility analysis, implying the medicine was not effective, but said there were no safety problems. Celgene is also developing mongersen in combination with another drug, ozanimod.

"We thank the patients and the investigators involved in the REVOLVE trial,” said Scott Smith, now Celgene's President and Chief Operating Officer, in another press release. “Crohn’s disease is a debilitating condition with few effective long-term treatment options. While we are disappointed with the results of REVOLVE, we remain committed to advancing our portfolio of novel medicines for patients suffering from this disease and other inflammatory bowel disorders.”
 

Latest posts

Back
Top